Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LYL273 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LYL273 | EXPERIMENTAL | Single infusion of LYL273 at the dose assigned to an individual participant. All participants will receive the same investigational therapy with the dose administered dependent upon the dose level they are assigned to in a sequential manner. |
| Name | Type | Description |
|---|---|---|
| LYL273 | DRUG | Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.) |
Inclusion Criteria: * Adults \> 18 years old * Clinical and histopathological diagnosis of relapsed or refractory metastatic colorectal cancer * Eastern Cooperative Oncology Group performance status of 0 or 1 * Limited liver disease (less than 7 lesions with largest lesion less than 3 cm) * No surg...
Top 20 of 77 competitors
LYL273 is an investigational small molecule being developed for the treatment of colorectal cancer. It is currently being studied in a Phase 1 clinical trial for patients with relapsed or refractory metastatic colorectal cancer (mCRC). The drug is not yet approved and remains in clinical development.
LYL273 targets GCC, a protein that is expressed in colorectal cancer cells. By targeting GCC, LYL273 is designed to interfere with cancer cell signaling. This mechanism is being evaluated in early-stage clinical trials to assess its safety and potential efficacy in patients with colorectal cancer.
LYL273 is being developed by Lyell Immunopharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LYEL. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with relapsed or refractory metastatic colorectal cancer.
LYL273 is currently in Phase 1 clinical development. The drug is being studied in an open-label, uncontrolled trial that is actively recruiting participants. It has not received FDA approval and is considered an investigational agent. The trial is designed to evaluate safety and dosing in patients with colorectal cancer.
LYL273 is being evaluated in a single Phase 1 clinical trial with the identifier NCT05319314. This trial is titled 'LYL273 for Patients With Relapsed or Refractory mCRC' and is currently recruiting participants in the United States. The study plans to enroll approximately 155 patients with colorectal cancer.
Yes, LYL273 has received Fast Track designation from the U.S. Food and Drug Administration. This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. The drug remains in Phase 1 clinical testing.